

Figure 1



Linear Peptides


LATELRSQSLQTLQG - SEQ ID NO:49
SAKELRSQSIKTYSK - SEQ ID NO:50
LRELRSVSLQTTQG - SEQ ID NO:51
SPGPHSAQTEVIAT - SEQ ID NO:52
ESGPHSANTEIIVK - SEQ ID NO:53

Figure 2




Flow cytometric data comparing neutrophils present in BAL samples. Sessions 1, 2 and 3 are presented. The black solid bars show the baselines 5 day pre-LPS challenge. The grey solid bars depict the BAL data 6-hours post LPS challenge. The Chimera Antibody treatment significantly and dose dependently inhibited neutrophil infiltration. The grey hatched bars represent 24-hour data. (n=6, *$p \leq 0.05$, †$p \leq 0.01$, error bars represent standard deviation).

Figure 3



Hematological analysis of total circulating neutrophils (cell count). IV injection of 1 (open squares, □) and 10 mg/kg (closed circles, •) of the Chimera Antibody prevented inhaled LPS stimulation of circulating neutrophils. Both 1 and 10 mg/kg treatments are significantly reduced compared to the vehicle NHP (†) and 10 mg/kg treatment was also significantly reduced compared to the 1 mg/kg dose (*). Data are represented as total count per ul of blood (n=6, *$p \leq 0.05$ vs. 1 mg/kg, †$p \leq 0.01$ vs. vehicle, error bars represent standard deviation).

Figure 4



Inhibition human IL-8 stimulated neutrophil activation (increased CD11b surface expression). Various concentrations of the humanized penta-specific antibodies were pre-incubated with 10 nM hIL-8 prior to addition to purified human neutrophils. Data are expressed as mean values of 4 different donors (n=4). Bars represent standard error. All samples are compared to purified neutrophils stimulated with hIL-8 only (no mAb prior to addition to purified neutrophils). Humanized construct H0L10 and H0M0 are more effective at inhibiting hIL-8 stimulated CD11b surface expression.

Figure 5A

Mouse 2X656.35 mAb binding to target human chemokines.





Figure 5B


The Chimera Antibody (HcLc) mAb binding to human target chemokines.



hIL-18 run as a negative control

Figure 5C

Humanized mAbs binding to human target chemokines



hIL-18 run as a negative control